{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T08:19:16Z","timestamp":1775463556960,"version":"3.50.1"},"reference-count":0,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[1991,4,1]],"date-time":"1991-04-01T00:00:00Z","timestamp":670464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[1991,4]]},"abstract":"\n We have previously described that sodium ipodate (500 mg\/day, p.o.) is effective in normalizing serum T\n 3<\/jats:sub>\n and T\n 4<\/jats:sub>\n levels in most patients with Graves' hyperthyroidism. In this study, we examined serum T\n 3<\/jats:sub>\n , T\n 4<\/jats:sub>\n , and rT\n 3<\/jats:sub>\n levels in 14 hyperthyroid patients with Graves' disease during treatment with a lower dose (500 mg, every other day, p.o.) of sodium ipodate for a period of 3-30 weeks (mean 15.5 weeks). Three types of responses were observed. In group I (4 patients), both serum T\n 3<\/jats:sub>\n and T\n 4<\/jats:sub>\n were in the normal range at the end of treatment [baseline: mean \u00b1 SEM T\n 3<\/jats:sub>\n , 6.8 \u00b1 0.96 nmol\/L (normal 0.92-3.0)] and T\n 4<\/jats:sub>\n [256 \u00b1 44 nmol\/L (normal 62-167); post-ipodate: T\n 3<\/jats:sub>\n , 2.0 \u00b1 0.46 nmol\/L and T\n 4<\/jats:sub>\n 107 \u00b1 28 nmol\/L]. In group II (\n n<\/jats:italic>\n = 5), either serum T\n 3<\/jats:sub>\n (3 patients) or serum T\n 4<\/jats:sub>\n (2 patients) did not become normal (baseline: T\n 3<\/jats:sub>\n 7.7 \u00b1 1.1 and T\n 4<\/jats:sub>\n 228 \u00b1 3.9; post-ipodate: T\n 3<\/jats:sub>\n 2.9 \u00b1 0.57 and T\n 4<\/jats:sub>\n 188 \u00b1 27 nmol\/L). In group III (5 patients), neither serum T\n 3<\/jats:sub>\n nor serum T\n 4<\/jats:sub>\n returned to normal following ipodate treatment (baseline: T\n 3<\/jats:sub>\n 11.9 \u00b1 1.8 and T\n 4<\/jats:sub>\n 260 \u00b1 23; post-ipodate: T\n 3<\/jats:sub>\n 7.5 \u00b1 0.49 and T\n 4<\/jats:sub>\n 322 \u00b1 17 nmol\/L). The mean serum rT\n 3<\/jats:sub>\n concentration increased during ipodate treatment to a peak value of 100% above baseline and remained elevated (20-75% above baseline) throughout the study. Some improvement in hyperthyroidism was suggested by increase in body weight during ipodate treatment in most cases. The average body weight of patients increased by a maximum of 2.7 \u00b1 0.7 kg at week 2, and the pulse rate diminished from the mean baseline value of 101 \u00b1 3.1\/min to a nadir value of 84 \u00b1 2.8\/min at week 3(\n p<\/jats:italic>\n < 0.01). At the end of treatment, however, only group I patients (4 of 14, or 29%) demonstrated significant reduction in resting pulse rate (\n p<\/jats:italic>\n < 0.05). Treatment of Graves' disease with 500 mg every other day of sodium ipodate results in infrequent normalization of serum thyroid hormone levels or clinical features of hyperthyroidism. The minimal effective dose of sodium ipodate for treating hyperthyroidism is more than 500 mg every other day and probably close to 500 mg\/day.\n <\/jats:p>","DOI":"10.1089\/thy.1991.1.143","type":"journal-article","created":{"date-parts":[[2009,3,30]],"date-time":"2009-03-30T16:19:37Z","timestamp":1238429977000},"page":"143-146","source":"Crossref","is-referenced-by-count":2,"title":["Further Studies on the Long-Term Treatment of Graves' Hyperthyroidism with Ipodate: Assessment of a Minimal Effective Dose"],"prefix":"10.1177","volume":"1","author":[{"given":"Der-Chung","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sing-Yung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inder J.","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee-Ren","family":"Shian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warner","family":"Florsheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1991,4,1]]},"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.1991.1.143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.1991.1.143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:39:33Z","timestamp":1775461173000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.1991.1.143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,4]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1991,4]]}},"alternative-id":["10.1089\/thy.1991.1.143"],"URL":"https:\/\/doi.org\/10.1089\/thy.1991.1.143","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,4]]}}}